Under the agreement, Focus Diagnostics will gain the global rights to integrate HyBeacons PCR probe technology into its molecular diagnostic products and services.
HyBeacons probes are sequence specific hybridization probes, which contain two fluorophores per probe thereby creating a full-bodied fluorescent signal.
HyBeacons are easy to design which offers the ability to multiplex different color probes for the identification of multiple targets in a single reaction.
The products provide clear quantitative data during amplification and have capabilities with DNA and RNA targets.
Evogen president and CEO Hans Kastensmith said with the firm’s new licensing agreement Focus Diagnostics will incorporate firm’s HyBeacons probe technology into their molecular diagnostic offerings.
"This Agreement highlights the continued evolution of HyBeacons probe technology into an industry standard," Kastensmith added.